12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Recombinant Alpha1-Proteinase Inhibitor: Phase II started

Grifols began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate 100 and 200 mg Alpha-1 HC aerosol daily via nebulizer for 3 weeks in 30...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >